Matthew T Neal

US Patent:

20130281395, Oct 24, 2013

Filed:

Mar 22, 2013

Appl. No.:

13/848809

Inventors:

University of Pittsburgh - of the Commonwealth System of Higher Education - , US
Matthew D. Neal - Pittsburgh PA, US
David J. Hackam - Pittsburgh PA, US

International Classification:

A61K 31/7008
A61K 31/7034

US Classification:

514 35, 514 23, 514 53, 514 25, 536 172, 536 187

Abstract:

The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.

US Patent:

20210308162, Oct 7, 2021

Filed:

Feb 11, 2021

Appl. No.:

17/174018

Inventors:

- Pittsburgh PA, US
Matthew D. Neal - Pittsburgh PA, US
Chhinder P. Sodhi - Sewickley PA, US
David J. Hackam - Pittsburgh PA, US

Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA

International Classification:

A61K 31/7028
A61K 31/7008
A61K 31/7034
A61K 31/7024
A61K 31/351

Abstract:

The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.

US Patent:

20190374562, Dec 12, 2019

Filed:

Apr 17, 2019

Appl. No.:

16/386886

Inventors:

- Pittsburgh PA, US
Matthew D. Neal - Pittsburgh PA, US
David J. Hackam - Pittsburgh PA, US

Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA

International Classification:

A61K 31/7028
A61K 31/7008
A61K 31/7034
A61K 31/7024
A61K 31/351

Abstract:

The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.

US Patent:

20170095493, Apr 6, 2017

Filed:

Dec 19, 2016

Appl. No.:

15/383625

Inventors:

- Pittsburgh PA, US
Matthew D. Neal - Pittsburgh PA, US
David J. Hackam - Pittsburgh PA, US

Assignee:

University of Pittsburgh - of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61K 31/7028
A61K 31/351
A61K 31/7034

Abstract:

The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.

US Patent:

20150250809, Sep 10, 2015

Filed:

May 20, 2015

Appl. No.:

14/717349

Inventors:

- Pittsburgh PA, US
Matthew D. Neal - Pittsburgh PA, US
David J. Hackam - Pittsburgh PA, US

Assignee:

University of Pittsburgh - of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61K 31/7024
A61K 31/7034
A61K 31/7028

Abstract:

The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.